A-FABP Concentration Is More Strongly Associated with Cardiometabolic Risk Factors and the Occurrence of Metabolic Syndrome in Premenopausal Than in Postmenopausal Middle-Aged Women
Table 2
Concentration of A-FABP in cardiometabolic disturbances.
PRE
POST
MetS (−)
19.5 (13.5–23.8)
28.9 (21.5–48.4)
MetS (+)
35.5 (19.6–41.7)#
36.3 (26.9–47.0)
HOMA < 3.4
20.2 (13.5–25.8)
29.8 (23.4–47.9)
HOMA ≥ 3.4
36.0 (29.7–36.9)#
37.4 (29.5–58.7)
Elevated BP (−)
20.2 (13.0–24.9)
30.9 (24.1–52.0)
Elevated BP (+)
29.6 (23.2–36.0)#
34.0 (24.1–48.1)
HDL-C ≥ 50 mg/dL
17.6 (13.0–23.0)
29.1 (22.6–41.7)
HDL-C < 50 mg/dL
35.5 (21.9–41.7)#
48.1 (28.9–76.2)@
TC/HDL-C < 4
18.3 (13.0–23.8)
29.1 (23.4–47.9)
TC/HDL-C ≥ 4
31.4 (23.2–36.8)#
32.8 (25.3–48.1)
TG/HDL-C < 1.3
20.1 (13.3–25.3)
30.1 (22.6–47.9)
TG/HDL-C ≥ 1.3
28.4 (22.5–33.7)@
38.6 (28.9–59.3)
CRP mg/L < 1.0
16.2 (12.9–21.5)
24.9 (18.4–39.9)
CRP mg/L ≥ 1.0
23.2 (18.3–34.3)#
36.9 (27.8–54.5)@
BMI < 30
17.3 (13.0–21.3)
25.8 (20.5–32.6)
BMI ≥ 30
31.4 (22.8–36.9)#
46.0 (32.1–59.3)#
; ; . Elevated BP (≥130/≥85 mmHg) or hypertension treatment.
